CD44 and metastatic prostate carcinoma: The results of this study indicate when concentration of SB-3CT is 20μmol/L, mild to moderate synergistic effects with docetaxel are observed, which suggests combination of CD44 inhibitor and conventional chemotherapy may be the most favorable therapeutic strategy for future treatment of castration resistant or metastatic prostate cancer.